SBIR Phase I: Novel COVID-19 Dual-function Therapeutic/Vaccine Product

SBIR 第一阶段：新型 COVID-19 双功能治疗/疫苗产品

• 批准号: 2112166
• 负责人: Sang Van
• 金额: $ 25.6万
• 依托单位: PARAMITA THERAPEUTICS, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2022-11-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2112166&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; COVID; 19

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is to develop a new class of dual-function therapeutic/vaccine products that can prevent viruses from entering cells (therapeutic effect) while also stimulating immunity to viruses (vaccine effect). The proposal has immediate impact in that it seeks to synthesize a compound that can be used to treat patients with COVID-19, caused by SARS CoV-2. Specifically, the novel solution both prevents SARS-CoV-2 from entering human lung cells and stimulates immune cells, such as dendritic cells, resulting in immunization. The proposed solution is the only one that could be given to infected individuals as both a therapy and a vaccine. This Small Business Innovation Research (SBIR) Phase I project seeks to develop a new class of dual-function therapeutic/vaccine solutions. The proposed work is to synthesize a compound with multiple copies of a peptide from SARS-CoV-2 spike protein that could block the virus from entering host cells. It will also contain multiple copies of a peptide that could direct excess product to immune cells to serve as a vaccine to induce T cell responses and neutralizing antibodies. The multiple copies of the peptides are synthesized on a multivalent backbone using patented chemistry. This unique synthetic scheme allows for the rapid production of such multivalent conjugates, but proof-of-principle supporting the biologic activities of the proposed products is missing. The proposed studies will accomplish the synthesis and characterization of the dual-function compounds, resulting in selection of a lead candidate for subsequent development.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这一小企业创新研究项目的更广泛影响/商业潜力是开发一类新的双重功能治疗/疫苗产品，既能防止病毒进入细胞（治疗效果），又能刺激对病毒的免疫力（疫苗效果）。该提案旨在合成可用于治疗由SARS - CoV-2引起的COVID-19患者的化合物，因此具有立竿见影的效果。具体来说，这种新溶液既能阻止SARS-CoV-2进入人体肺细胞，又能刺激树突状细胞等免疫细胞，从而产生免疫。提出的解决方案是唯一一种既可以作为治疗又可以作为疫苗给予感染者的解决方案。这项小企业创新研究（SBIR）第一阶段项目旨在开发一类新的双功能治疗/疫苗解决方案。拟议的工作是合成一种含有SARS-CoV-2刺突蛋白肽的多个拷贝的化合物，该化合物可以阻止病毒进入宿主细胞。它还将含有一种多肽的多个拷贝，这种多肽可以将多余的产物引导到免疫细胞，作为疫苗，诱导T细胞反应并中和抗体。多肽的多个拷贝是利用专利化学在多价主链上合成的。这种独特的合成方案允许快速生产这种多价偶联物，但缺乏支持所提议产品生物活性的原理证明。所提出的研究将完成双功能化合物的合成和表征，从而为后续开发选择主要候选化合物。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。